Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals ...

Leerink Partners analyst Puneet Souda reiterated a Buy rating on Quanterix (QTRX – Research Report) today. The company’s shares ...

In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

On Friday, Geron Corp (GERN) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.14 or 3.16% from the prior close of $4.43. The stock opened at $4.47 and ...

On Friday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.6 which represents a slight increase of $0.06 or 3.90% from the prior close of $1.54. The stock opened at ...

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock.

On Thursday, Leerink Partners sustained their optimistic stance on Celldex (NASDAQ:CLDX) Therapeutics (NASDAQ:CLDX), maintaining an Outperform rating and a $78.00 price target for the stock. The ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Outperform to Market Perform. There are 2,432 funds or ...